What You Should Know:
– ScreenPoint Medical, a provider of AI-powered breast cancer screening solutions, acquires Biomediq A/S, a research-based company specializing in quantitative imaging biomarkers. Financial details of the acquisition were not disclosed.
– ScreenPoint’s industry-leading Transpara AI platform will now incorporate Biomediq’s advanced risk analysis technology, which enables automated analysis of 2D and 3D mammograms to assess future breast cancer risk. This integration builds upon a decade of close collaboration between the two companies.
Enhancing Risk Prediction with AI
Biomediq’s technology utilizes a Mammographic Texture Risk biomarker that identifies tissue heterogeneity associated with both short- and long-term breast cancer risk. This complements Transpara’s existing capabilities in lesion detection and breast density assessment.
A 2023 study published in Radiology highlighted the potential of combining these technologies. The study, “Assessing Breast Cancer Risk by Combining AI for Lesion Detection and Mammographic Texture,” demonstrated that integrating Transpara’s tools with Biomediq’s texture model significantly improved risk prediction. Furthermore, the research indicated that using Transpara to identify high-risk women for additional imaging could double the early detection of interval cancers.
Strengthening Transpara’s Capabilities
Transpara, the most clinically validated breast AI solution on the market, provides radiologists with a “second pair of eyes” to aid in early cancer detection and reduce recall rates. The platform’s latest version, Transpara 2.1, offers enhanced features, including automated breast density assessment and a robust temporal comparison tool.
Collaboration and Expertise
To accelerate the development of Transpara’s risk assessment capabilities, ScreenPoint has welcomed Dr. Andreas D. Lauritzen, the first author of the Radiology study, to its team. Professor Mads Nielsen, co-founder of Biomediq, will continue to serve as an advisor.
“Risk-stratified screening has long been proposed to optimize screening for patients and better use resources,” said Professor Nico Karssemeijer, co-founder and Chief Scientific Officer of ScreenPoint Medical. “We are excited to add the Biomediq risk analysis technology to enhance the capabilities of Transpara to improve performance for mammography-based breast cancer risk assessment. This is a game-changing step in providing accurate and consistent breast cancer detection and care for all women.”
